Ole J. Bjerrum

New safe medicines faster: a proposition for a pan-European research effort.

Centrally-mediated antinociceptive actions of GABA(A) receptor agonists in the rat spared nerve injury model of neuropathic pain.

How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004.

Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain.

The importance of genetic background on pain behaviours and pharmacological sensitivity in the rat spared serve injury model of peripheral neuropathic pain.

Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development.

Effective integration of systems biology, biomarkers, biosimulation, and modeling in streamlining drug development.

Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain.

The EUFEPS workshop on institutional peer review "The ultimate tool to advance the pharmaceutical sciences?" A continuing story.

Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.

Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies.

Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.

Excellence in education and training advances competitiveness of the pharmaceutical industry in Europe.